Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials.
Where this comes from
- Record sourced from PubMed, PMID 20519717.
- Also identified by DOI 10.1126/scitranslmed.3001087.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Selection biomarkers are disease-associated analytes whose measurement is either an essential step in patient screening or the primary objective of a clinical trial. The public database ClinicalTrials.gov contains information on most active phase III oncology clinical trials that can be examined for trends in the development of cancer therapies. But for selection biomarkers, such information is not easily accessible and so has not been examined in a comprehensive way. Here we provide a global analysis of selection biomarkers currently in use in the oncology phase III trial arena.
Medical subject headings
- Biomarkers, Tumor
- Clinical Trials, Phase III as Topic
- Patient Selection